IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio庐 in Combination with 碍贰驰罢搁鲍顿础庐 (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company, has scheduled a conference call and webcast for August 11, 2025, at 8:30 AM ET to reveal topline results from its pivotal Phase 3 trial (IOB-013/KN-D18). The trial evaluates Cylembio, an investigational immune-modulatory cancer vaccine, in combination with 碍贰驰罢搁鲍顿础庐 versus 碍贰驰罢搁鲍顿础庐 alone for first-line treatment of advanced melanoma.
The study focuses on patients with unresectable or metastatic melanoma, with management hosting a live discussion of the results. A replay will be available on the company's website after the event.
IO Biotech (NASDAQ:IOBT), azienda biofarmaceutica in fase clinica, ha programmato una conference call e un webcast per il 11 agosto 2025 alle 8:30 AM ET per comunicare i risultati principali del suo studio pivotale di Fase 3 (IOB-013/KN-D18). Lo studio valuta Cylembio, un vaccino oncologico immunomodulatore sperimentale, in combinazione con 碍贰驰罢搁鲍顿础庐 rispetto a 碍贰驰罢搁鲍顿础庐 da sola nel trattamento di prima linea del melanoma avanzato.
Lo studio riguarda pazienti con melanoma non asportabile o metastatico; la direzione commenter脿 i risultati in diretta. Una registrazione sar脿 disponibile sul sito web della societ脿 dopo l'evento.
IO Biotech (NASDAQ:IOBT), compa帽铆a biofarmac茅utica en fase cl铆nica, ha programado una llamada de conferencia y un webcast para el 11 de agosto de 2025 a las 8:30 AM ET para dar a conocer los resultados principales de su ensayo pivotal de Fase 3 (IOB-013/KN-D18). El estudio eval煤a Cylembio, una vacuna oncol贸gica inmunomoduladora en investigaci贸n, en combinaci贸n con 碍贰驰罢搁鲍顿础庐 frente a 碍贰驰罢搁鲍顿础庐 sola para el tratamiento de primera l铆nea del melanoma avanzado.
El estudio se centra en pacientes con melanoma irresecable o metast谩sico; la direcci贸n realizar谩 una presentaci贸n en vivo sobre los resultados. Despu茅s del evento, habr谩 una repetici贸n disponible en la web de la compa帽铆a.
IO Biotech (NASDAQ:IOBT), 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓臧� 2025雲� 8鞗� 11鞚� 鞓れ爠 8鞁� 30攵� ET鞐� 旎嵓霟办姢 旖� 氚� 鞗轨簮鞀ろ姼毳� 鞐挫柎 欤检殧 瓴瓣臣(韱彪澕鞚�)毳� 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 鞚� 欷戩稊鞝侅澑 3靸�(Phase 3) 鞁滍棙( IO B-013/KN-D18 )鞚� 鞁ろ棙鞝� 氅挫棴臁办爤 鞎� 氚膘嫚鞚� Cylembio毳� 碍贰驰罢搁鲍顿础庐鞕� 氤戩毄頃� 瓴届毎鞕� 碍贰驰罢搁鲍顿础庐 雼弲鞚� 牍勱祼頃� 歆勴枆靹� 頋戩儔膦呾潣 1彀� 旃橂搿滌劀 韽夑皜頃╇媹雼�.
鞐瓣惮電� 鞝堨牅臧� 攵堦皜電ロ晿瓯半倶 鞝勳澊靹膘澑 頋戩儔膦� 頇橃瀽毳� 雽�靸侅溂搿� 頃橂┌, 瓴届榿歆勳澊 瓴瓣臣毳� 鞁れ嫓臧勳溂搿� 靹る獏頃╇媹雼�. 頄夓偓 頉� 須岇偓 鞗轨偓鞚错姼鞐愳劀 鞛箔旆�(雲鬼檾氤�)毳� 鞝滉车頃� 鞓堨爼鞛呺媹雼�.
IO Biotech (NASDAQ:IOBT), soci茅t茅 biopharmaceutique en phase clinique, a programm茅 une conf茅rence t茅l茅phonique et un webcast pour le 11 ao没t 2025 脿 8h30 (ET) afin de communiquer les r茅sultats principaux de son essai pivotal de Phase 3 (IOB-013/KN-D18). L'茅tude 茅value Cylembio, un vaccin anticanc茅reux immunomodulateur en d茅veloppement, en association avec 碍贰驰罢搁鲍顿础庐 versus 碍贰驰罢搁鲍顿础庐 seul en traitement de premi猫re intention du m茅lanome avanc茅.
L'茅tude porte sur des patients atteints d'un m茅lanome non r茅s茅cable ou m茅tastatique ; la direction pr茅sentera et discutera les r茅sultats en direct. Un enregistrement sera disponible sur le site Web de la soci茅t茅 apr猫s l'茅v茅nement.
IO Biotech (NASDAQ:IOBT), ein biopharmazeutisches Unternehmen in der klinischen Entwicklung, hat eine Telefonkonferenz und einen Webcast f眉r den 11. August 2025 um 8:30 Uhr ET angesetzt, um die Topline-Ergebnisse seiner pivotalen Phase-3-Studie (IOB-013/KN-D18) vorzustellen. Die Studie untersucht Cylembio, einen experimentellen immunmodulierenden Krebsimpfstoff, in Kombination mit 碍贰驰罢搁鲍顿础庐 gegen眉ber 碍贰驰罢搁鲍顿础庐 allein als Erstlinientherapie beim fortgeschrittenen Melanom.
Untersucht werden Patienten mit nicht resektablem oder metastasiertem Melanom; die Gesch盲ftsf眉hrung wird die Ergebnisse live diskutieren. Eine Aufzeichnung wird nach der Veranstaltung auf der Website des Unternehmens verf眉gbar sein.
- None.
- None.
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline results of the pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvant) in combination with pembrolizumab vs. pembrolizumab alone as a first-line treatment for unresectable or metastatic (advanced) melanoma.
Webcast and Conference Call Information
The IO Biotech management team will host a webcast/conference call on Monday, August 11, 2025, at 8:30 a.m. ET to discuss the topline results from the Phase 3 trial of Cylembio. Those who would like to participate may access the live webcast or register in advance for the teleconference . A replay of the webcast will be available on the IO Biotech website following the live event.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win庐 platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, Cylembio庐, in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with Merck鈥檚 anti-PD-1 therapy, 碍贰驰罢搁鲍顿础庐 (pembrolizumab), has been granted a Breakthrough Therapy Designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit . Follow us on our social media channels on and X ().
颁辞苍迟补肠迟蝉:听
滨苍惫别蝉迟辞谤蝉听
Maryann Cimino, Director of Investor Relations听听
IO Biotech, Inc.听
617-710-7305听
听
Media听
Julie Funesti听
Edelman
917-498-1967
FAQ
When will IO Biotech (IOBT) announce Phase 3 trial results for Cylembio?
What is the purpose of IO Biotech's Phase 3 trial for Cylembio?
What type of drug is IO Biotech's Cylembio?
How can investors access IO Biotech's Phase 3 results presentation?
What is the trial identification number for IO Biotech's Phase 3 Cylembio study?
